Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 61 entries
Sorted by: Best Match Show Resources per page
Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium.

The journal of pathology. Clinical research

Howat WJ, Blows FM, Provenzano E, Brook MN, Morris L, Gazinska P, Johnson N, McDuffus LA, Miller J, Sawyer EJ, Pinder S, van Deurzen CH, Jones L, Sironen R, Visscher D, Caldas C, Daley F, Coulson P, Broeks A, Sanders J, Wesseling J, Nevanlinna H, Fagerholm R, Blomqvist C, Heikkilä P, Ali HR, Dawson SJ, Figueroa J, Lissowska J, Brinton L, Mannermaa A, Kataja V, Kosma VM, Cox A, Brock IW, Cross SS, Reed MW, Couch FJ, Olson JE, Devillee P, Mesker WE, Seyaneve CM, Hollestelle A, Benitez J, Perez JI, Menéndez P, Bolla MK, Easton DF, Schmidt MK, Pharoah PD, Sherman ME, García-Closas M.
PMID: 27499890
J Pathol Clin Res. 2014 Dec 04;1(1):18-32. doi: 10.1002/cjp2.3. eCollection 2015 Jan.

Breast cancer risk factors and clinical outcomes vary by tumour marker expression. However, individual studies often lack the power required to assess these relationships, and large-scale analyses are limited by the need for high throughput, standardized scoring methods. To...

Cite
Howat WJ, Blows FM, Provenzano E, et al. Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium. J Pathol Clin Res. 2014;1(1):18-32doi: 10.1002/cjp2.3.
Howat, W. J., Blows, F. M., Provenzano, E., Brook, M. N., Morris, L., Gazinska, P., Johnson, N., McDuffus, L. A., Miller, J., Sawyer, E. J., Pinder, S., van Deurzen, C. H., Jones, L., Sironen, R., Visscher, D., Caldas, C., Daley, F., Coulson, P., Broeks, A., Sanders, J., Wesseling, J., Nevanlinna, H., Fagerholm, R., Blomqvist, C., Heikkilä, P., Ali, H. R., Dawson, S. J., Figueroa, J., Lissowska, J., Brinton, L., Mannermaa, A., Kataja, V., Kosma, V. M., Cox, A., Brock, I. W., Cross, S. S., Reed, M. W., Couch, F. J., Olson, J. E., Devillee, P., Mesker, W. E., Seyaneve, C. M., Hollestelle, A., Benitez, J., Perez, J. I., Menéndez, P., Bolla, M. K., Easton, D. F., Schmidt, M. K., Pharoah, P. D., Sherman, M. E., & García-Closas, M. (2015). Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium. The journal of pathology. Clinical research, 1(1), 18-32. https://doi.org/10.1002/cjp2.3
Howat, William J, et al. "Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium." The journal of pathology. Clinical research vol. 1,1 (2015): 18-32. doi: https://doi.org/10.1002/cjp2.3
Howat WJ, Blows FM, Provenzano E, Brook MN, Morris L, Gazinska P, Johnson N, McDuffus LA, Miller J, Sawyer EJ, Pinder S, van Deurzen CH, Jones L, Sironen R, Visscher D, Caldas C, Daley F, Coulson P, Broeks A, Sanders J, Wesseling J, Nevanlinna H, Fagerholm R, Blomqvist C, Heikkilä P, Ali HR, Dawson SJ, Figueroa J, Lissowska J, Brinton L, Mannermaa A, Kataja V, Kosma VM, Cox A, Brock IW, Cross SS, Reed MW, Couch FJ, Olson JE, Devillee P, Mesker WE, Seyaneve CM, Hollestelle A, Benitez J, Perez JI, Menéndez P, Bolla MK, Easton DF, Schmidt MK, Pharoah PD, Sherman ME, García-Closas M. Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium. J Pathol Clin Res. 2014 Dec 04;1(1):18-32. doi: 10.1002/cjp2.3. eCollection 2015 Jan. PMID: 27499890; PMCID: PMC4858117.
Copy Download .nbib Format: NLM
Effect of bile absorption coefficients on the estimation of liver tissue optical properties and related implications in discriminating healthy and tumorous samples.

Biomedical optics express

Nachabé R, Evers DJ, Hendriks BH, Lucassen GW, van der Voort M, Wesseling J, Ruers TJ.
PMID: 21412465
Biomed Opt Express. 2011 Feb 15;2(3):600-14. doi: 10.1364/BOE.2.000600.

We investigated differences between healthy tissue and metastatic tumor from ex vivo human partial liver resections using diffuse optical spectroscopy with a fiber optic probe. We extracted various physiological and morphological parameters from the spectra. During evaluation of the...

Cite
Nachabé R, Evers DJ, Hendriks BH, et al. Effect of bile absorption coefficients on the estimation of liver tissue optical properties and related implications in discriminating healthy and tumorous samples. Biomed Opt Express. 2011;2(3):600-14doi: 10.1364/BOE.2.000600.
Nachabé, R., Evers, D. J., Hendriks, B. H., Lucassen, G. W., van der Voort, M., Wesseling, J., & Ruers, T. J. (2011). Effect of bile absorption coefficients on the estimation of liver tissue optical properties and related implications in discriminating healthy and tumorous samples. Biomedical optics express, 2(3), 600-14. https://doi.org/10.1364/BOE.2.000600
Nachabé, Rami, et al. "Effect of bile absorption coefficients on the estimation of liver tissue optical properties and related implications in discriminating healthy and tumorous samples." Biomedical optics express vol. 2,3 (2011): 600-14. doi: https://doi.org/10.1364/BOE.2.000600
Nachabé R, Evers DJ, Hendriks BH, Lucassen GW, van der Voort M, Wesseling J, Ruers TJ. Effect of bile absorption coefficients on the estimation of liver tissue optical properties and related implications in discriminating healthy and tumorous samples. Biomed Opt Express. 2011 Feb 15;2(3):600-14. doi: 10.1364/BOE.2.000600. PMID: 21412465; PMCID: PMC3047365.
Copy Download .nbib Format: NLM
Electroproduction of pi 0 on the proton near threshold.

Physical review letters

Bergstrom J, Blok HP, de Jager CW, de Vries H, Deady M, Jans E, Karen PH, Lapikás L, Mitchell JH, Norum BE, van den Brink HB, Welch TP, Wesseling J.
PMID: 10046582
Phys Rev Lett. 1992 Nov 09;69(19):2761-2764. doi: 10.1103/PhysRevLett.69.2761.

No abstract available.

Cite
Bergstrom J, Blok HP, de Jager CW, et al. Electroproduction of pi 0 on the proton near threshold. Phys Rev Lett. 1992;69(19):2761-2764doi: 10.1103/PhysRevLett.69.2761.
Bergstrom, J., Blok, H. P., de Jager CW, de Vries H, Deady, M., Jans, E., Karen, P. H., Lapikás, L., Mitchell, J. H., Norum, B. E., van den Brink HB, Welch, T. P., & Wesseling, J. (1992). Electroproduction of pi 0 on the proton near threshold. Physical review letters, 69(19), 2761-2764. https://doi.org/10.1103/PhysRevLett.69.2761
Bergstrom, et al. "Electroproduction of pi 0 on the proton near threshold." Physical review letters vol. 69,19 (1992): 2761-2764. doi: https://doi.org/10.1103/PhysRevLett.69.2761
Bergstrom J, Blok HP, de Jager CW, de Vries H, Deady M, Jans E, Karen PH, Lapikás L, Mitchell JH, Norum BE, van den Brink HB, Welch TP, Wesseling J. Electroproduction of pi 0 on the proton near threshold. Phys Rev Lett. 1992 Nov 09;69(19):2761-2764. doi: 10.1103/PhysRevLett.69.2761. PMID: 10046582.
Copy Download .nbib Format: NLM
Hexadecapole interacting boson approximation structure functions in neodymium isotopes.

Physical review. C, Nuclear physics

Blasi N, Bordewijk JA, de Jager CW, De Leo R, de Vries H, Harakeh MN, Micheletti S, Perrino R, Pignanelli M, Sandor RK, van der Werf SY, Wesseling J.
PMID: 9968635
Phys Rev C Nucl Phys. 1993 Apr;47(4):R1347-R1350. doi: 10.1103/physrevc.47.r1347.

No abstract available.

Cite
Blasi N, Bordewijk JA, de Jager CW, et al. Hexadecapole interacting boson approximation structure functions in neodymium isotopes. Phys Rev C Nucl Phys. 1993;47(4):R1347-R1350doi: 10.1103/physrevc.47.r1347.
Blasi, N., Bordewijk, J. A., de Jager CW, De Leo R, de Vries H, Harakeh, M. N., Micheletti, S., Perrino, R., Pignanelli, M., Sandor, R. K., van der Werf SY, & Wesseling, J. (1993). Hexadecapole interacting boson approximation structure functions in neodymium isotopes. Physical review. C, Nuclear physics, 47(4), R1347-R1350. https://doi.org/10.1103/physrevc.47.r1347
Blasi, et al. "Hexadecapole interacting boson approximation structure functions in neodymium isotopes." Physical review. C, Nuclear physics vol. 47,4 (1993): R1347-R1350. doi: https://doi.org/10.1103/physrevc.47.r1347
Blasi N, Bordewijk JA, de Jager CW, De Leo R, de Vries H, Harakeh MN, Micheletti S, Perrino R, Pignanelli M, Sandor RK, van der Werf SY, Wesseling J. Hexadecapole interacting boson approximation structure functions in neodymium isotopes. Phys Rev C Nucl Phys. 1993 Apr;47(4):R1347-R1350. doi: 10.1103/physrevc.47.r1347. PMID: 9968635.
Copy Download .nbib Format: NLM
Structure-Activity Studies with Bis-Amidines That Potentiate Gram-Positive Specific Antibiotics against Gram-Negative Pathogens.

ACS infectious diseases

Wesseling CMJ, Slingerland CJ, Veraar S, Lok S, Martin NI.
PMID: 34766746
ACS Infect Dis. 2021 Dec 10;7(12):3314-3335. doi: 10.1021/acsinfecdis.1c00466. Epub 2021 Nov 12.

Pentamidine, an FDA-approved antiparasitic drug, was recently identified as an outer membrane disrupting synergist that potentiates erythromycin, rifampicin, and novobiocin against Gram-negative bacteria. The same study also described a preliminary structure-activity relationship using commercially available pentamidine analogues. We here...

Cite
Wesseling CMJ, Slingerland CJ, Veraar S, et al. Structure-Activity Studies with Bis-Amidines That Potentiate Gram-Positive Specific Antibiotics against Gram-Negative Pathogens. ACS Infect Dis. 2021;7(12):3314-3335doi: 10.1021/acsinfecdis.1c00466.
Wesseling, C. M. J., Slingerland, C. J., Veraar, S., Lok, S., & Martin, N. I. (2021). Structure-Activity Studies with Bis-Amidines That Potentiate Gram-Positive Specific Antibiotics against Gram-Negative Pathogens. ACS infectious diseases, 7(12), 3314-3335. https://doi.org/10.1021/acsinfecdis.1c00466
Wesseling, Charlotte M J, et al. "Structure-Activity Studies with Bis-Amidines That Potentiate Gram-Positive Specific Antibiotics against Gram-Negative Pathogens." ACS infectious diseases vol. 7,12 (2021): 3314-3335. doi: https://doi.org/10.1021/acsinfecdis.1c00466
Wesseling CMJ, Slingerland CJ, Veraar S, Lok S, Martin NI. Structure-Activity Studies with Bis-Amidines That Potentiate Gram-Positive Specific Antibiotics against Gram-Negative Pathogens. ACS Infect Dis. 2021 Dec 10;7(12):3314-3335. doi: 10.1021/acsinfecdis.1c00466. Epub 2021 Nov 12. PMID: 34766746.
Copy Download .nbib Format: NLM
Seasonal Influence on the Performance of Low-Cost NO.

Sensors (Basel, Switzerland)

Ratingen SV, Vonk J, Blokhuis C, Wesseling J, Tielemans E, Weijers E.
PMID: 34883922
Sensors (Basel). 2021 Nov 27;21(23). doi: 10.3390/s21237919.

Low-cost sensor technology has been available for several years and has the potential to complement official monitoring networks. The current generation of nitrogen dioxide (NO

Cite
Ratingen SV, Vonk J, Blokhuis C, et al. Seasonal Influence on the Performance of Low-Cost NO. Sensors (Basel). 2021;21(23)doi: 10.3390/s21237919.
Ratingen, S. V., Vonk, J., Blokhuis, C., Wesseling, J., Tielemans, E., & Weijers, E. (2021). Seasonal Influence on the Performance of Low-Cost NO. Sensors (Basel, Switzerland), 21(23), . https://doi.org/10.3390/s21237919
Ratingen, Sjoerd van, et al. "Seasonal Influence on the Performance of Low-Cost NO." Sensors (Basel, Switzerland) vol. 21,23 (2021). doi: https://doi.org/10.3390/s21237919
Ratingen SV, Vonk J, Blokhuis C, Wesseling J, Tielemans E, Weijers E. Seasonal Influence on the Performance of Low-Cost NO. Sensors (Basel). 2021 Nov 27;21(23). doi: 10.3390/s21237919. PMID: 34883922.
Copy Download .nbib Format: NLM
Physics-Based Simulations to Predict the Differential Effects of Motor Control and Musculoskeletal Deficits on Gait Dysfunction in Cerebral Palsy: A Retrospective Case Study.

Frontiers in human neuroscience

Falisse A, Pitto L, Kainz H, Hoang H, Wesseling M, Van Rossom S, Papageorgiou E, Bar-On L, Hallemans A, Desloovere K, Molenaers G, Van Campenhout A, De Groote F, Jonkers I.
PMID: 32132911
Front Hum Neurosci. 2020 Feb 18;14:40. doi: 10.3389/fnhum.2020.00040. eCollection 2020.

Physics-based simulations of walking have the theoretical potential to support clinical decision-making by predicting the functional outcome of treatments in terms of walking performance. Yet before using such simulations in clinical practice, their ability to identify the main treatment...

Cite
Falisse A, Pitto L, Kainz H, et al. Physics-Based Simulations to Predict the Differential Effects of Motor Control and Musculoskeletal Deficits on Gait Dysfunction in Cerebral Palsy: A Retrospective Case Study. Front Hum Neurosci. 2020;14:40doi: 10.3389/fnhum.2020.00040.
Falisse, A., Pitto, L., Kainz, H., Hoang, H., Wesseling, M., Van Rossom, S., Papageorgiou, E., Bar-On, L., Hallemans, A., Desloovere, K., Molenaers, G., Van Campenhout, A., De Groote, F., & Jonkers, I. (2020). Physics-Based Simulations to Predict the Differential Effects of Motor Control and Musculoskeletal Deficits on Gait Dysfunction in Cerebral Palsy: A Retrospective Case Study. Frontiers in human neuroscience, 1440. https://doi.org/10.3389/fnhum.2020.00040
Falisse, Antoine, et al. "Physics-Based Simulations to Predict the Differential Effects of Motor Control and Musculoskeletal Deficits on Gait Dysfunction in Cerebral Palsy: A Retrospective Case Study." Frontiers in human neuroscience vol. 14 (2020): 40. doi: https://doi.org/10.3389/fnhum.2020.00040
Falisse A, Pitto L, Kainz H, Hoang H, Wesseling M, Van Rossom S, Papageorgiou E, Bar-On L, Hallemans A, Desloovere K, Molenaers G, Van Campenhout A, De Groote F, Jonkers I. Physics-Based Simulations to Predict the Differential Effects of Motor Control and Musculoskeletal Deficits on Gait Dysfunction in Cerebral Palsy: A Retrospective Case Study. Front Hum Neurosci. 2020 Feb 18;14:40. doi: 10.3389/fnhum.2020.00040. eCollection 2020. PMID: 32132911; PMCID: PMC7040166.
Copy Download .nbib Format: NLM
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.

The Lancet. Oncology

Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S, Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JMS, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF.
PMID: 34902335
Lancet Oncol. 2021 Dec 10; doi: 10.1016/S1470-2045(21)00589-1. Epub 2021 Dec 10.

BACKGROUND: Previous studies have independently validated the prognostic relevance of residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from several independent cohorts in a pooled patient-level analysis to evaluate the relationship of RCB with long-term prognosis across...

Cite
Yau C, Osdoit M, van der Noordaa M, et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 2021;doi: 10.1016/S1470-2045(21)00589-1.
Yau, C., Osdoit, M., van der Noordaa, M., Shad, S., Wei, J., de Croze, D., Hamy, A. S., Laé, M., Reyal, F., Sonke, G. S., Steenbruggen, T. G., van Seijen, M., Wesseling, J., Martín, M., Del Monte-Millán, M., López-Tarruella, S., Boughey, J. C., Goetz, M. P., Hoskin, T., Gould, R., Valero, V., Edge, S. B., Abraham, J. E., Bartlett, J. M. S., Caldas, C., Dunn, J., Earl, H., Hayward, L., Hiller, L., Provenzano, E., Sammut, S. J., Thomas, J. S., Cameron, D., Graham, A., Hall, P., Mackintosh, L., Fan, F., Godwin, A. K., Schwensen, K., Sharma, P., DeMichele, A. M., Cole, K., Pusztai, L., Kim, M. O., van 't Veer, L. J., Esserman, L. J., & Symmans, W. F. (2021). Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. The Lancet. Oncology, . https://doi.org/10.1016/S1470-2045(21)00589-1
Yau, Christina, et al. "Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients." The Lancet. Oncology vol. (2021). doi: https://doi.org/10.1016/S1470-2045(21)00589-1
Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S, Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JMS, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 2021 Dec 10; doi: 10.1016/S1470-2045(21)00589-1. Epub 2021 Dec 10. PMID: 34902335.
Copy Download .nbib Format: NLM
Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial.

JAMA oncology

van der Voort A, van Ramshorst MS, van Werkhoven ED, Mandjes IA, Kemper I, Vulink AJ, Oving IM, Honkoop AH, Tick LW, van de Wouw AJ, Mandigers CM, van Warmerdam LJ, Wesseling J, Vrancken Peeters MT, Linn SC, Sonke GS.
PMID: 34014249
JAMA Oncol. 2021 Jul 01;7(7):978-984. doi: 10.1001/jamaoncol.2021.1371.

IMPORTANCE: Primary analysis of the TRAIN-2 study showed high pathologic complete response rates after neoadjuvant chemotherapy with or without anthracyclines plus dual ERBB2 (formerly HER2) blockade.OBJECTIVE: To evaluate 3-year event-free survival (EFS) and overall survival (OS) of an anthracycline-free...

Cite
van der Voort A, van Ramshorst MS, van Werkhoven ED, et al. Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial. JAMA Oncol. 2021;7(7):978-984doi: 10.1001/jamaoncol.2021.1371.
van der Voort, A., van Ramshorst, M. S., van Werkhoven, E. D., Mandjes, I. A., Kemper, I., Vulink, A. J., Oving, I. M., Honkoop, A. H., Tick, L. W., van de Wouw, A. J., Mandigers, C. M., van Warmerdam, L. J., Wesseling, J., Vrancken Peeters, M. T., Linn, S. C., & Sonke, G. S. (2021). Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial. JAMA oncology, 7(7), 978-984. https://doi.org/10.1001/jamaoncol.2021.1371
van der Voort, Anna, et al. "Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial." JAMA oncology vol. 7,7 (2021): 978-984. doi: https://doi.org/10.1001/jamaoncol.2021.1371
van der Voort A, van Ramshorst MS, van Werkhoven ED, Mandjes IA, Kemper I, Vulink AJ, Oving IM, Honkoop AH, Tick LW, van de Wouw AJ, Mandigers CM, van Warmerdam LJ, Wesseling J, Vrancken Peeters MT, Linn SC, Sonke GS. Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial. JAMA Oncol. 2021 Jul 01;7(7):978-984. doi: 10.1001/jamaoncol.2021.1371. PMID: 34014249; PMCID: PMC8138752.
Copy Download .nbib Format: NLM
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.

The Lancet. Oncology

Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S, Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JMS, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF.
PMID: 34902335
Lancet Oncol. 2022 Jan;23(1):149-160. doi: 10.1016/S1470-2045(21)00589-1. Epub 2021 Dec 11.

BACKGROUND: Previous studies have independently validated the prognostic relevance of residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from several independent cohorts in a pooled patient-level analysis to evaluate the relationship of RCB with long-term prognosis across...

Cite
Yau C, Osdoit M, van der Noordaa M, et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 2021;23(1):149-160doi: 10.1016/S1470-2045(21)00589-1.
Yau, C., Osdoit, M., van der Noordaa, M., Shad, S., Wei, J., de Croze, D., Hamy, A. S., Laé, M., Reyal, F., Sonke, G. S., Steenbruggen, T. G., van Seijen, M., Wesseling, J., Martín, M., Del Monte-Millán, M., López-Tarruella, S., Boughey, J. C., Goetz, M. P., Hoskin, T., Gould, R., Valero, V., Edge, S. B., Abraham, J. E., Bartlett, J. M. S., Caldas, C., Dunn, J., Earl, H., Hayward, L., Hiller, L., Provenzano, E., Sammut, S. J., Thomas, J. S., Cameron, D., Graham, A., Hall, P., Mackintosh, L., Fan, F., Godwin, A. K., Schwensen, K., Sharma, P., DeMichele, A. M., Cole, K., Pusztai, L., Kim, M. O., van 't Veer, L. J., Esserman, L. J., & Symmans, W. F. (2022). Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. The Lancet. Oncology, 23(1), 149-160. https://doi.org/10.1016/S1470-2045(21)00589-1
Yau, Christina, et al. "Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients." The Lancet. Oncology vol. 23,1 (2022): 149-160. doi: https://doi.org/10.1016/S1470-2045(21)00589-1
Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S, Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JMS, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 2022 Jan;23(1):149-160. doi: 10.1016/S1470-2045(21)00589-1. Epub 2021 Dec 11. PMID: 34902335.
Copy Download .nbib Format: NLM
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.

The Lancet. Oncology

Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S, Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JMS, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF.
PMID: 34902335
Lancet Oncol. 2022 Jan;23(1):149-160. doi: 10.1016/S1470-2045(21)00589-1. Epub 2021 Dec 11.

BACKGROUND: Previous studies have independently validated the prognostic relevance of residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from several independent cohorts in a pooled patient-level analysis to evaluate the relationship of RCB with long-term prognosis across...

Cite
Yau C, Osdoit M, van der Noordaa M, et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 2021;23(1):149-160doi: 10.1016/S1470-2045(21)00589-1.
Yau, C., Osdoit, M., van der Noordaa, M., Shad, S., Wei, J., de Croze, D., Hamy, A. S., Laé, M., Reyal, F., Sonke, G. S., Steenbruggen, T. G., van Seijen, M., Wesseling, J., Martín, M., Del Monte-Millán, M., López-Tarruella, S., Boughey, J. C., Goetz, M. P., Hoskin, T., Gould, R., Valero, V., Edge, S. B., Abraham, J. E., Bartlett, J. M. S., Caldas, C., Dunn, J., Earl, H., Hayward, L., Hiller, L., Provenzano, E., Sammut, S. J., Thomas, J. S., Cameron, D., Graham, A., Hall, P., Mackintosh, L., Fan, F., Godwin, A. K., Schwensen, K., Sharma, P., DeMichele, A. M., Cole, K., Pusztai, L., Kim, M. O., van 't Veer, L. J., Esserman, L. J., & Symmans, W. F. (2022). Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. The Lancet. Oncology, 23(1), 149-160. https://doi.org/10.1016/S1470-2045(21)00589-1
Yau, Christina, et al. "Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients." The Lancet. Oncology vol. 23,1 (2022): 149-160. doi: https://doi.org/10.1016/S1470-2045(21)00589-1
Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S, Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JMS, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 2022 Jan;23(1):149-160. doi: 10.1016/S1470-2045(21)00589-1. Epub 2021 Dec 11. PMID: 34902335.
Copy Download .nbib Format: NLM
Structure-Activity Studies with Bis-Amidines That Potentiate Gram-Positive Specific Antibiotics against Gram-Negative Pathogens.

ACS infectious diseases

Wesseling CMJ, Slingerland CJ, Veraar S, Lok S, Martin NI.
PMID: 34766746
ACS Infect Dis. 2021 Dec 10;7(12):3314-3335. doi: 10.1021/acsinfecdis.1c00466. Epub 2021 Nov 12.

Pentamidine, an FDA-approved antiparasitic drug, was recently identified as an outer membrane disrupting synergist that potentiates erythromycin, rifampicin, and novobiocin against Gram-negative bacteria. The same study also described a preliminary structure-activity relationship using commercially available pentamidine analogues. We here...

Cite
Wesseling CMJ, Slingerland CJ, Veraar S, et al. Structure-Activity Studies with Bis-Amidines That Potentiate Gram-Positive Specific Antibiotics against Gram-Negative Pathogens. ACS Infect Dis. 2021;7(12):3314-3335doi: 10.1021/acsinfecdis.1c00466.
Wesseling, C. M. J., Slingerland, C. J., Veraar, S., Lok, S., & Martin, N. I. (2021). Structure-Activity Studies with Bis-Amidines That Potentiate Gram-Positive Specific Antibiotics against Gram-Negative Pathogens. ACS infectious diseases, 7(12), 3314-3335. https://doi.org/10.1021/acsinfecdis.1c00466
Wesseling, Charlotte M J, et al. "Structure-Activity Studies with Bis-Amidines That Potentiate Gram-Positive Specific Antibiotics against Gram-Negative Pathogens." ACS infectious diseases vol. 7,12 (2021): 3314-3335. doi: https://doi.org/10.1021/acsinfecdis.1c00466
Wesseling CMJ, Slingerland CJ, Veraar S, Lok S, Martin NI. Structure-Activity Studies with Bis-Amidines That Potentiate Gram-Positive Specific Antibiotics against Gram-Negative Pathogens. ACS Infect Dis. 2021 Dec 10;7(12):3314-3335. doi: 10.1021/acsinfecdis.1c00466. Epub 2021 Nov 12. PMID: 34766746; PMCID: PMC8669655.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 61 entries